



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Bravecto 250 mg Chewable Tablets for Small Dogs (>4.5 – 10 kg)

Vm 01708/5021

•	24 January 2024	Alignment of product information with the national SPC/QRD template to align with QRD v 9.0 product information.
•	19 January 2024	Other changes relating to the excipients of the finished product.
•	23 August 2023	Minor change to sample preparation method as part of finished product testing.
•	13 June 2023	Unlimited renewal
•	18 November 2022	The grouped variation is to add two new therapeutic indications for Bravecto chewable tablets for dogs: for persistent tick killing activity from 7 days to 12 weeks after treatment for Ixodes hexagonus and for reduction of the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 weeks. The grouped variation is to add two new therapeutic indications for Bravecto chewable tablets for dogs: for persistent tick killing activity from 7 days to 12 weeks after treatment for Ixodes hexagonus and for reduction of the risk of infection with Dipylidium caninum via transmission by Ctenocephalides felis for up to 12 weeks
•	02 August 2022	To add an alternative irradiation test method for the pork liver flavour excipient from the SPF supplier used in Bravecto chewable tablets.
•	23 June 2022	Change in name of manufacturer of the active substance.
•	20 April 2022	Introduction of an alternative manufacturer of an excipient.
•	04 February 2022	Addition of a new therapeutic indication
•	21 December 2021	Change in the specification limits of an excipient.
•	03 September 2021	Changes to the labelling and/or package leaflet.